JPMorgan Chase & Co. Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its price target dropped by investment analysts at JPMorgan Chase & Co. from $123.00 to $110.00 in a research note issued on Friday,MarketScreener reports. The firm presently has an “overweight” rating on the healthcare product maker’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 13.53% from the stock’s current price.

ABT has been the subject of several other reports. Jefferies Financial Group decreased their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday. Leerink Partners cut their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. Benchmark decreased their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday. Argus lowered their price objective on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Finally, Citigroup cut their price objective on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $121.00.

Abbott Laboratories Price Performance

ABT stock opened at $96.89 on Friday. The stock’s 50 day moving average is $107.89 and its two-hundred day moving average is $118.65. Abbott Laboratories has a 52-week low of $93.92 and a 52-week high of $139.06. The company has a market capitalization of $168.75 billion, a PE ratio of 27.14, a P/E/G ratio of 1.57 and a beta of 0.79. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The business’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares in the company, valued at $4,526,575.12. The trade was a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last 90 days. 0.46% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Abbott Laboratories

Several institutional investors have recently modified their holdings of ABT. Vanguard Group Inc. lifted its position in Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares during the last quarter. State Street Corp grew its position in Abbott Laboratories by 2.1% in the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares during the last quarter. Capital International Investors increased its stake in shares of Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after purchasing an additional 1,614,706 shares during the period. J. Stern & Co. LLP raised its holdings in shares of Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after buying an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors raised its holdings in shares of Abbott Laboratories by 1.0% during the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after buying an additional 400,400 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Preliminary settlement reached in six shareholder derivative suits tied to Abbott’s U.S. infant‑formula business, reducing litigation overhang for investors. Read More.
• Positive Sentiment: New data on Cancerguard MCED (multi‑cancer early detection) presented at AACR 2026 — important for Abbott’s growth thesis since the Exact Sciences deal expanded its oncology diagnostics exposure. Continued clinical progress supports longer‑term revenue upside. Read More.
• Positive Sentiment: Insiders added roughly $3.1M of stock, and a number of analysts still see upside — some calling the post‑acquisition pullback a buying opportunity given valuation and Abbott’s dividend track record. Read More. Read More.
• Neutral Sentiment: Q1 results: adjusted EPS $1.15 (vs. $1.14 est.) and revenue $11.16B (vs. $10.99B); company set FY 2026 adjusted EPS guidance to $5.38–$5.58 and Q2 guide to $1.25–$1.31, explicitly including ~$0.20 of dilution from the Exact Sciences acquisition. Investors are parsing beat vs. the guidance change. Read More.
• Neutral Sentiment: Earnings call transcript and analyst commentary emphasize medical‑device strength offset by Diagnostics/Nutrition softness and acquisition-related margin pressure — useful for active traders but mixed for near‑term stock direction. Read More.
• Negative Sentiment: Market reaction: shares fell after the print because Abbott trimmed guidance and flagged Nutrition weakness and margin compression; coverage shows the takeover (≈$21–23B) is dilutive near term. Read More.
• Negative Sentiment: Many brokers lowered price targets and some cut forecasts following Q1/guidance — several firms kept positive ratings but reduced targets (examples include RBC, Jefferies, Raymond James, Citi and others), amplifying short‑term selling pressure. Read More.
• Negative Sentiment: Analyst notes and headlines highlighted the EPS guidance cut and Nutrition slump as primary reasons for the earlier drop — these remain catalysts to watch for the next quarter. Read More.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.